Cargando…

Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples

BACKGROUND: Correct identification of the EGFR c.2369C>T p.(Thr790Met) variant is key to decide on a targeted therapeutic strategy for patients with acquired EGFR TKI resistance in non-small cell lung cancer. The aim of this study was to evaluate the correct detection of this variant in 12 tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keppens, Cleo, Dequeker, Elisabeth M. C., Rouleau, Etienne, ’t Hart, Nils, Bubendorf, Lukas, Dufraing, Kelly, Garrec, Céline, Guéguen, Paul, Lamy, Aude, Marchetti, Antonio, Pauwels, Patrick, Ryska, Ales, Tack, Véronique, Tornillo, Luigi, Van Casteren, Kaat, von der Thüsen, Jan H., Zwaenepoel, Karen, Lissenberg-Witte, Birgit, Thunnissen, Erik, Schuuring, Ed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193365/ https://www.ncbi.nlm.nih.gov/pubmed/32357863 http://dx.doi.org/10.1186/s12885-020-06831-3

Ejemplares similares

Molecular pathology testing for non-small cell lung cancer: an observational study of elements currently present in request forms and result reports and the opinion of different stakeholders
por: Dufraing, Kelly, et al.
Publicado: (2022)

Variation in nomenclature of somatic variants for selection of oncological therapies: Can we reach a consensus soon?
por: Keppens, Cleo, et al.
Publicado: (2019)

A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer
por: Keppens, Cleo, et al.
Publicado: (2018)

PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation
por: Keppens, Cleo, et al.
Publicado: (2020)

Managing Deviating EQA Results: A Survey to Assess the Corrective and Preventive Actions of Medical Laboratories Testing for Oncological Biomarkers
por: Keppens, Cleo, et al.
Publicado: (2020)

Causes behind error rates for predictive biomarker testing: the utility of sending post-EQA surveys
por: Keppens, Cleo, et al.
Publicado: (2020)

Thr698Thr (nt2369) polymorphism on CACNA1A gene and head pain severity in familial migraine
por: Meamar, Rokhsareh, et al.
Publicado: (2013)

The Relevance of External Quality Assessment for Molecular Testing for ALK Positive Non-Small Cell Lung Cancer: Results from Two Pilot Rounds Show Room for Optimization
por: Tembuyser, Lien, et al.
Publicado: (2014)

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
por: Del Re, Marzia, et al.
Publicado: (2016)

European follow-up of incorrect biomarker results for colorectal cancer demonstrates the importance of quality improvement projects
por: Keppens, Cleo, et al.
Publicado: (2019)

Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories
por: Tack, Véronique, et al.
Publicado: (2018)

Biomarker testing in oncology – Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL
por: Dufraing, K., et al.
Publicado: (2020)

PB2369: PERIPHERAL T CELL LYMPHOMA: EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS
por: Charfi, Maha, et al.
Publicado: (2023)

Results of a worldwide external quality assessment of cfDNA testing in lung Cancer
por: Fairley, Jennifer A., et al.
Publicado: (2022)

2369. Prescribing Choices and C. difficile Infection Risk: A Longitudinal Cohort Study of Nursing Home Residents in Ontario, Canada
por: Antoine. Brown, Kevin, et al.
Publicado: (2019)

Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey
por: Deans, Zandra C., et al.
Publicado: (2017)

IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing
por: Deans, Zandra C., et al.
Publicado: (2019)

International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA
por: Keppens, Cleo, et al.
Publicado: (2018)

Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study
por: Dufraing, Kelly, et al.
Publicado: (2019)

Early detection of circulating tumor DNA and successful treatment with osimertinib in thr790met-positive leptomeningeal metastatic lung cancer: A case report
por: Xu, Li-Qing, et al.
Publicado: (2022)

THR Simulator – the software for generating radiographs of THR prosthesis
por: Wu, Tai-Yin, et al.
Publicado: (2009)

Non-Small-Cell Lung Cancer-Sensitive Detection of the p.Thr790Met EGFR Alteration by Preamplification before PNA-Mediated PCR Clamping and Pyrosequencing
por: Billaud, Amandine, et al.
Publicado: (2020)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
por: Xiang, Chan, et al.
Publicado: (2021)

Guidance for laboratories performing molecular pathology for cancer patients
por: Cree, Ian A, et al.
Publicado: (2014)

Erratum. Urine Complement Proteins and the Risk of Kidney Disease Progression and Mortality in Type 2 Diabetes. Diabetes Care 2018;41:2361–2369
por: Vaisar, Tomas, et al.
Publicado: (2019)

2369. Clinical Experience With Telavancin for Treatment of Patients With Monomicrobial S. aureus Infections (Vancomycin MIC ≥1 μg/mL) From TOUR™
por: Jacobs, Micah, et al.
Publicado: (2018)

The art of obtaining a high yield of cell-free DNA from urine
por: Augustus, Elien, et al.
Publicado: (2020)

Structural insights into drug development strategy targeting EGFR T790M/C797S
por: Zhu, Su-Jie, et al.
Publicado: (2018)

Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors
por: Jia, Yong, et al.
Publicado: (2016)

Expert opinion on NSCLC small specimen biomarker testing — Part 1: Tissue collection and management
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022)

Expert opinion on NSCLC small specimen biomarker testing — Part 2: Analysis, reporting, and quality assessment
por: Penault-Llorca, Frédérique, et al.
Publicado: (2022)

Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens: Number 2 in the Series “Pathology for the clinician” Edited by Peter Dorfmüller and Alberto Cavazza
por: Bubendorf, Lukas, et al.
Publicado: (2017)

Silent variant in F8:c.222G>T (p.Thr74Thr) causes a partial exon skipping in a patient with mild hemophilia A
por: Letelier, Anna, et al.
Publicado: (2021)

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S
por: Lategahn, Jonas, et al.
Publicado: (2019)

C/EBPβ-Thr217 Phosphorylation Stimulates Macrophage Inflammasome Activation and Liver Injury
por: Buck, Martina, et al.
Publicado: (2016)

Substitution of Thr572 to Ala in mouse c-Myb attenuates progression of early erythroid differentiation
por: Kitagawa, Kyoko, et al.
Publicado: (2020)

Coronin-1 is phosphorylated at Thr-412 by protein kinase Cα in human phagocytic cells
por: Oku, Teruaki, et al.
Publicado: (2021)

Testing for ROS1 in non-small cell lung cancer: a review with recommendations
por: Bubendorf, Lukas, et al.
Publicado: (2016)

External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different
por: Dodson, Andrew, et al.
Publicado: (2019)

Anaphylatoxin C5a Regulates 6-Sulfo-LacNAc Dendritic Cell Function in Human through Crosstalk with Toll-Like Receptor-Induced CREB Signaling
por: Zaal, Anouk, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_oifan4s2cln0q5adhq7l3v6htr